No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Mayinglong Pharmaceutical Group Co., LTD. is a prominent Chinese entity primarily engaged in the manufacturing, wholesale, and retail of a diverse array of pharmaceutical products. Its extensive offerings encompass treatments for hemorrhoid, gynecological, cough, and skin conditions, alongside functional foods, traditional Chinese medicine drink tablets, and various medical devices. The company also facilitates sales through online channels. Expanding its operations, it additionally manages and runs its own hospitals. Headquartered in Wuhan, China, Mayinglong Pharmaceutical Group Co., LTD. possesses a rich history, having been founded in 1582.
www.mayinglong.cnNo one on the platform currently holds 600993.SS.
No tracked institution reports a position in 600993.SS as of their last filing.
No one on the platform has traded 600993.SS yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 25.8% | 40.1% | 33.5% | — | — | — |
| Rev. Growth % | 3.7% | 6.7% | ||||
| Profit Margin % | 15.0% | 14.1% | 13.7% | |||
| Free Cash Flow Margin % | 12.4% | 11.0% | 11.9% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $4.2B | +3.5% | $1.54 | $1.53–$1.56 | — | 2 |
| 2027 | $4.6B | +9.7% | $1.72 | $1.70–$1.73 | — | 2 |
| 2028 | $5.0B | +8.1% | $1.90 | $1.84–$1.96 | — | 2 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 600993.SSMayinglong Pharmaceutical Group Co., Ltd. | $22.25 | -0.36% | $9.6B | — |
| 002550.SZChangzhou Qianhong Biopharma CO.,LTD | $6.31 | -0.00% | $7.7B | — |
| 002626.SZXiamen Kingdomway Group Company | $16.18 | +0.25% | $9.9B | — |
| 600129.SSChongqing Taiji Industry(Group) Co.,Ltd | $13.32 | -0.67% | $7.3B | — |
| 600216.SSZhejiang Medicine Co., Ltd. |
| $12.37 |
| -0.96% |
| $11.9B |
| — |
| 600267.SSZhejiang Hisun Pharmaceutical Co., Ltd. | $11.37 | +0.62% | $13.4B | — |
| 600285.SSHenan Lingrui Pharmaceutical Co., Ltd. | $19.07 | -1.04% | $10.8B | — |
Source: Financial Modeling Prep · peers by sector/industry